Arcadia Biosciences Reports on Shareholder Vote

TL;DR

Arcadia Biosciences held a shareholder vote on June 25th, details to follow.

AI Summary

Arcadia Biosciences, Inc. filed an 8-K on July 1, 2024, reporting on a meeting held on June 25, 2024, where security holders voted on certain matters. The filing does not disclose the specific proposals voted on or their outcomes.

Why It Matters

This filing indicates a shareholder meeting occurred, which could signal significant corporate decisions or changes being made by Arcadia Biosciences.

Risk Assessment

Risk Level: medium — The filing is a procedural update about a shareholder vote, but the lack of detail on the proposals and outcomes introduces uncertainty.

Key Players & Entities

• Arcadia Biosciences, Inc. (company) — Registrant
• June 25, 2024 (date) — Date of earliest event reported
• July 1, 2024 (date) — Date of report

FAQ

Filing Documents

• rkda-20240625.htm (8-K) — 64KB
• 0000950170-24-079602.txt ( ) — 175KB
• rkda-20240625.xsd (EX-101.SCH) — 24KB
• rkda-20240625_htm.xml (XML) — 5KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. At the annual meeting of stockholders of Arcadia Biosciences, Inc. (the "Company") held on June 25, 2024 (the "Annual Meeting"), stockholders holding and entitled to vote 682,593 shares of common stock of the Company, or approximately 50.08% of the total outstanding shares of common stock on the record date for the Annual Meeting, were present in person or by proxy. At the Annual Meeting, the stockholders voted on the following four proposals, each of which is described in detail in the definitive proxy statement filed with the Securities and Exchange Commission on May 16, 2024. The final results for each of the matters considered at the Annual Meeting were as follows: PROPOSAL I: Election of Directors The director nominees were elected to serve as a Class III directors until the Company's annual meeting of stockholders in 2027, or until their successors are duly elected and qualified, or their earlier resignation, death, or removal. Due to plurality election, votes could only be cast in favor of or withheld from the nominees and thus votes against were not applicable. The results of the election were as follows: DIRECTOR NOMINEE FOR WITHHELD BROKER NON-VOTES Amy Yoder 160,017 21,356 501,220 Lilian Shackelford Murray 149,613 31,760 501,220 PROPOSAL II: Ratification of Selection of Independent Registered Public Accountants The appointment of Deloitte & Touche LLP as the Company's independent registered public accountants for the year ending December 31, 2024, was ratified by the affirmative votes of the stockholders. There were no broker non-votes on this proposal. The results of the ratification were as follows: FOR AGAINST ABSTAIN 666,133 13,547 2,913 PROPOSAL III: Approval of an Amendment to the 2015 Omnibus Equity Incentive Plan The Company's shareholders approved the amendment to our 2015 Omnibus Equity Incentive Plan by the votes set forth in the t

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ARCADIA BIOSCIENCES, INC. Date: July 1, 2024 By: /s/ THOMAS J. SCHAEFER Thomas J. Schaefer, Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR